Company | Eli Lilly and Company |
Ticker | LLY (NYSE) |
Reporting Period | Q2 2026 (quarter ended June 30, 2026) |
Earnings Date | August 5, 2026 — Earnings Call at 10:00 AM ET |
Prepared | August 4, 2026 |
Sector ETF (Benchmark) | XLV (Health Care Select Sector SPDR) |
Key Takeaway: The setup favors a beat on revenue — consensus at ~$20.6B implies a deceleration from Q1's $19.8B that looks conservative given Mounjaro's continued volume surge and Foundayo's early launch momentum — but the EPS bar is complicated by a large one-time rebate adjustment in Q1 that will not repeat, and the single biggest swing factor is whether tirzepatide gross-to-net pricing deteriorates further than the market expects.
Heading into Q2 2026, Lilly's fundamental setup is constructive: the Street is modeling ~$20.6B in revenue and ~$6.68 in non-GAAP EPS, both of which appear achievable given the company's track record of beating by wide margins (averaging 8–12% revenue upside over the past four quarters). Management raised full-year guidance by $2B at the Q1 print and guided to $82–$85B for the year, implying a back-half ramp that requires Q2 to deliver at or above current consensus. Estimate revisions have been broadly stable since the Q1 beat — revenue consensus for Q2 has barely moved from the post-Q1 baseline of ~$20.5B — suggesting the Street is not aggressively chasing the beat, which leaves room for upside. The stock has rallied ~8% since the April 30 print and trades at ~27x NTM P/E, a premium that prices in continued execution but not perfection. The key wildcard is
Foundayo (orforglipron) early launch metrics: management guided to a gradual ramp with DTC advertising beginning in Q3, but any evidence of faster-than-expected new-to-class patient uptake — or, conversely, access friction at the third major PBM (CVS Caremark coverage began June 1) — could move the stock meaningfully in either direction. The Novo Nordisk lawsuit over GLP-1 advertising (filed July 21) adds headline noise but is unlikely to affect Q2 financials; retatrutide NDA filing on track for H2 2026 is a positive pipeline catalyst that the market is already beginning to price.
Key Takeaway: Consensus at $20.6B revenue and $6.68 non-GAAP EPS represents a
manageable bar given LLY's recent beat cadence. Tirzepatide consolidated revenue (~$13.0B consensus) is the bigger swing factor — any upside there flows directly to EPS given high incremental margins. The EPS bar looks optically low vs. Q1's $8.55 due to the absence of the Q1 one-time rebate adjustment and higher expected R&D spend.
KPI | Q1 2026 Actual | Q2 2025 Actual (Prior Year) | Q2 2026 Consensus Estimate | YoY Change | FY 2026 Guidance (Midpoint) | Consensus vs. Guidance |
Total Revenue ($B) | $19.80B | $15.56B | $20.62B | +32.5% | $83.5B (midpoint) | ~+0.1% vs. implied run-rate |
Non-GAAP EPS (Diluted) | $8.55 | $6.31 | $6.68 | +5.8% | $36.25 (midpoint) | ~−7.6% vs. implied run-rate |
Mounjaro Revenue ($B) | $8.66B | $5.20B | $8.88B | +70.8% | $35.9B FY (consensus) | N/A — no product-level guidance |
Zepbound Revenue ($B) | $4.16B | $3.38B | $4.66B | +37.9% | $19.5B FY (consensus) | N/A — no product-level guidance |
Tirzepatide Consolidated ($B) | $12.82B | $8.58B | $13.03B | +51.9% | $52.9B FY (consensus) | N/A — no product-level guidance |
Gross Margin % | 81.9% | ~82.5% (est.) | ~81–82% (est.) | ~flat to −50bps | 47–48.5% Perf. Margin | N/A |
Source: Visible Alpha Consensus and Actuals Data; LLY Q1 2026 Earnings Release (April 30, 2026). Note: Q2 2026 Consensus Estimates as of August 4, 2026. Non-GAAP EPS consensus reflects a step-down from Q1 due to the absence of the favorable one-time rebate/discount adjustment (~$0.50–$0.60 benefit in Q1) and higher expected R&D spend. Gross Margin % for Q2 2025 is an estimate based on reported segment data.
Quarter | Revenue Reported ($B) | Revenue Consensus ($B) | Rev. Surprise % | EPS Reported | EPS Consensus | EPS Surprise % | Result |
Q1 2026 | $19.80B | $17.51B | +13.1% | $8.55 | $6.78 | +26.1% | Beat |
Q4 2025 | $19.29B | $17.99B | +7.2% | $7.54 | $6.91 | +9.1% | Beat |
Q3 2025 | $17.60B | $16.06B | +9.6% | $7.02 | $5.91 | +18.8% | Beat |
Q2 2025 | $15.56B | $14.76B | +5.4% | $6.31 | $5.63 | +12.1% | Beat |
Q1 2025 | $12.73B | $12.62B | +0.9% | $3.34 | $3.26 | +2.5% | Beat |
Q4 2024 | $13.53B | $13.51B | +0.2% | $5.32 | $5.11 | +4.1% | Beat |
Q3 2024 | $11.44B | $12.16B | −6.0% | $1.18 | $2.18 | −45.9% | Miss |
Q2 2024 | N/A — not in VA | N/A — not in VA | N/A | N/A — not in VA | N/A — not in VA | N/A | N/A |
Source: Visible Alpha Consensus and Actuals Data. Pattern: LLY has beaten revenue consensus in 6 of the last 7 reported quarters, with the sole miss in Q3 2024 driven by manufacturing/supply constraints that have since been resolved; the recent beat cadence has accelerated materially, averaging ~7–13% revenue upside in the last four quarters, setting a high bar for Q2 2026.
Key Takeaway: Management raised full-year guidance by $2B on both the top and bottom of the revenue range at the Q1 print (April 30), and
no formal guidance revision has occurred since. Tone has remained confident, with the ADA Investor Event (June 6) reinforcing the pipeline narrative without changing financial targets. The Medicare Bridge program extension through December 2027 is a structural positive that management has framed as a gradual 2026 tailwind accelerating into 2027.
Metric | Initial Guidance (Q1 2026 Earnings — April 30, 2026) | Revised Guidance | Current Consensus | Note |
Full-Year Revenue | $82.0B – $85.0B | — | $85.4B | Raised $2B at Q1 print from prior $80–$83B; consensus sits slightly above midpoint, implying market expects continued upside |
Full-Year Non-GAAP EPS | $35.50 – $37.00 | — | $34.83 | Raised $2 at Q1 print from prior $33.50–$35.00; consensus now sits ~4% below guidance midpoint, reflecting EPS estimate drift lower since mid-July (see Revision Tracker) |
Non-GAAP Performance Margin | 47.0% – 48.5% | — | ~47–48% (est.) | Unchanged; raised from 46.0–47.5% at Q1 print; driven by revenue leverage |
Tax Rate | 18% – 19% | — | ~18–19% (est.) | Unchanged since Q1 print |
Full-Year Price Headwind | Low-to-mid teens % headwind | — | Consistent with guidance | Management reiterated at Q1 call; pricing pressure from Mounjaro/Zepbound gross-to-net is the primary driver; no change in tone |
Medicare Bridge Access | Gradual 2026 ramp, accelerating in 2027 | Program extended through Dec 2027 (CMS, April 2026); $50/mo. cap effective July 1, 2026 | Positive structural tailwind | ↑ Positive post-earnings development; management framed as gradual 2026 tailwind with larger 2027 impact; up to 20M eligible Medicare beneficiaries |
Foundayo (orforglipron) Launch | Gradual ramp; DTC advertising in Q3; Medicare access July 1 | CVS Caremark coverage confirmed June 1 (all 3 major PBMs now covered); DTC launched June 8 (NBA broadcast) | Ahead of initial timeline | ↑ Access milestone achieved faster than guided; DTC launched slightly ahead of Q3 target; T2D FDA submission planned by end of Q2 2026 |
Source: LLY Q1 2026 Earnings Release and Earnings Call Transcript (April 30, 2026); LLY ADA Investor Event Transcript (June 6, 2026); LLY Press Releases (May–July 2026).
Key Takeaway: Revenue estimates for Q2 2026 and FY 2026 have been remarkably stable since the Q1 beat — a sign the Street is not aggressively chasing upside. The more notable move is in
EPS, where the FY 2026 consensus has drifted ~5% below the guidance midpoint since mid-July, likely reflecting analysts modeling higher R&D and SG&A spend for Foundayo's DTC launch and retatrutide NDA preparation. This gap is a potential source of upside if management reaffirms or raises EPS guidance on the Q2 call.
KPI (Period) | Estimate ~5 Days Post Q1 Earnings (May 8, 2026) | Current Estimate (Aug 4, 2026) | Estimate Δ (%) | Initial Guidance (Q1 Call) | Current Guidance | Guidance Δ | Consensus vs. Guidance (%) |
Total Revenue (Q2 2026) | $20.54B | $20.62B | +0.4% | N/A (quarterly not guided) | N/A | N/A | N/A |
Total Revenue (FY 2026) | $85.09B | $85.38B | +0.3% | $82.0B – $85.0B | Unchanged | — | +1.0% above midpoint |
Non-GAAP EPS (Q2 2026) | $8.82 | $6.68 | −24.3% | N/A (quarterly not guided) | N/A | N/A | N/A |
Non-GAAP EPS (FY 2026) | $36.64 | $34.83 | −4.9% | $35.50 – $37.00 | Unchanged | — | −3.9% below midpoint |
Tirzepatide Consolidated (Q2 2026) | $12.76B | $13.03B | +2.1% | N/A | N/A | N/A | N/A |
Tirzepatide Consolidated (FY 2026) | $51.49B | $52.91B | +2.8% | N/A | N/A | N/A | N/A |
Source: Visible Alpha Consensus and Actuals Data (revision history table, weekly frequency, May 8 – August 4, 2026). Note: The sharp Q2 EPS estimate decline from $8.82 (May 8) to $6.68 (Aug 4) is primarily a modeling artifact — the May 8 estimate likely still embedded the Q1 one-time rebate/discount adjustment benefit that analysts subsequently stripped out as they refined Q2 models. The FY 2026 EPS drift from $36.64 to $34.83 (−4.9%) is more meaningful and reflects genuine downward revision pressure, likely from higher opex assumptions for Foundayo DTC and retatrutide NDA preparation. Tirzepatide estimates have drifted modestly higher (+2–3%), consistent with continued volume momentum.
Key Takeaway: LLY has outperformed XLV and the S&P 500 since the Q1 2026 earnings print, driven primarily by
estimate revisions and pipeline catalysts (retatrutide TRIUMPH-1 data, Foundayo launch) rather than multiple expansion — the NTM P/E has actually compressed slightly from ~30x to ~27x over the past 6 months, meaning the +7% 6-month price gain was entirely earnings-driven. The 1-month pullback of ~7% reflects the Novo Nordisk lawsuit headline and broader pharma sector rotation, not a fundamental deterioration.
Stock Performance Summary (Since Q1 2026 Earnings — April 30, 2026 to August 4, 2026):
Security | Return Since Q1 Earnings (Apr 30 – Aug 4, 2026) | 1-Month Return | 3-Month Return | 12-Month Return |
LLY | ~+8% (est.) | −7.0% | +15.3% | +46.4% |
XLV (Health Care ETF) | ~+3% (est.) | ~−2% (est.) | ~+8% (est.) | ~+15% (est.) |
S&P 500 | ~+5% (est.) | ~−1% (est.) | ~+10% (est.) | ~+20% (est.) |
Source: LLY Stock Performance Decomposition data (Implied platform). LLY NTM multiples as of August 4, 2026: EV/EBITDA 21.8x, P/E 27.3x, EV/Sales 11.1x.
Valuation Context: Over the past 12 months, LLY's +46% price gain was driven almost entirely by earnings growth rather than multiple expansion — the NTM P/E contracted slightly from ~27.5x to ~27.3x, while EV/EBITDA compressed from ~22.1x to ~21.8x. The 3-month +15% rally was a mix of earnings revision upside (+12% multiple expansion) and estimate revisions. The 1-month −7% pullback was driven by multiple compression (−8%), suggesting the Novo lawsuit and sector rotation created a valuation air pocket that could reverse quickly on a strong Q2 print.
Key Events Since Q1 Earnings (April 30, 2026):
Key Takeaway: The most important development since Q1 earnings is the
Medicare Bridge program launch (July 1) and the completion of full PBM coverage for Foundayo — together these represent the two largest access milestones management had been working toward, and their impact on Q2 Foundayo and Zepbound volumes will be a key focus on the earnings call. The Novo lawsuit is headline noise, not a fundamental risk.
Key Takeaway: Insider activity since the Q1 print is minimal and unremarkable — one small 10b5-1 planned sale by an EVP and a routine sale by the Lilly Endowment (a long-standing institutional holder).
No open-market discretionary buys or unusual sale clusters; the absence of insider buying at current prices is consistent with the stock's premium valuation rather than a negative signal.
Name | Title | Transaction Type | Shares | Approx. Value | Transaction Date | Note |
Ilya Yuffa | EVP & President, LLY USA & Global Capabilities | 10b5-1 Planned Sale | 2,500 | ~$2.9M (est.) | June 10, 2026 | Pre-planned 10b5-1 sale; routine; not discretionary. Retains ~29,804 shares post-transaction. |
Lilly Endowment Inc. | Former 10% Shareholder (institutional) | Open Market Sale | 15,828 | ~$18.5M (est.) | May 6, 2026 | Lilly Endowment is a long-standing institutional holder that has been gradually reducing its position over many years; routine portfolio management, not a signal of insider concern. Retains ~91.9M shares. |
Source: SEC Form 4 Filings Database (Insider Transaction Data). Filing dates: Yuffa — June 11, 2026; Lilly Endowment — May 7, 2026. No open-market discretionary buys were filed in the past 60 days.
Key Takeaway: Peer commentary from the past 60 days is broadly
constructive for LLY's Q2 2026 print: Novo Nordisk's Q2 beat on GLP-1 volume confirms robust category demand, while Amgen's maritime program and Viking's VK2735 represent longer-term competitive pipeline risks rather than near-term revenue threats. The most actionable read-through is NVO's Q2 GLP-1 volume strength, which de-risks LLY's tirzepatide volume assumptions heading into the print.
Scope Note: Only peer commentary from the past 60 days (June 5 – August 4, 2026) that specifically addresses Q2 2026 performance or Q3/Q4 2026 forward outlook is included below. Commentary that merely recaps Q1 2026 or earlier historical periods has been excluded.
Read-Through Type: Direct near-term market read-through (same reporting period, same category)
Theme | NVO Commentary (Q2 2026 Results — August 4, 2026) | LLY Read-Through |
GLP-1 Volume Demand | Q2 adjusted sales +7% at CER to DKK 78.5B (~$12.1B), beating consensus of ~$10.9B. Growth driven by "GLP-1 volume growth across geographies." Wegovy pill reached 5M+ prescriptions since U.S. launch; weekly TRx exceeded 265,000 for the week ending July 17. | Strongly positive. Confirms robust category demand in Q2 across both U.S. and international markets. LLY's tirzepatide volume consensus (~$13.0B) looks achievable given NVO's volume beat in the same quarter. |
Oral GLP-1 Market Dynamics | Wegovy pill (oral semaglutide) is "the market leader among branded obesity medications in the US" by new patient starts. Launched in UAE (June) and UK (July) with "encouraging early uptake." EMA approved Wegovy pill in July (OASIS 4 data: up to 16.6% weight loss). | Mixed. NVO's oral leadership by new patient starts is a competitive data point for Foundayo, but LLY's Foundayo has no food/water restrictions and showed superiority vs. oral semaglutide in ACHIEVE-3 (9.2% vs. 5.3% weight loss). The oral market is expanding, not zero-sum. |
Pricing / Rebate Dynamics | Q2 growth partly driven by "favourable US rebate adjustments in the quarter" — a one-time benefit. Pricing pressure remains a structural headwind for both companies. | Neutral to slightly cautious. LLY also benefited from a one-time rebate adjustment in Q1; if NVO's Q2 had a similar one-time benefit, it suggests the underlying volume growth rate may be slightly lower than the headline implies. Watch for LLY's gross-to-net commentary. |
Full-Year Guidance Raise | NVO raised FY 2026 guidance: adjusted sales now 0% to −6% CER (vs. prior −4% to −12%). CEO: "The increased US GLP-1 momentum, combined with continued growth and new launches in International Operations, has led us to further raise our 2026 guidance." | Positive. NVO's guidance raise driven by GLP-1 momentum is a category-level positive that supports LLY's own guidance range of $82–$85B. Increases probability LLY also raises or reaffirms at the high end. |
Stock Reaction (NVO −6% on beat) | NVO stock fell ~6% despite the revenue beat and guidance raise, likely reflecting: (1) ziltivekimab cardiovascular drug failure (July 31), (2) market fatigue with GLP-1 names, and (3) concerns about competitive dynamics from LLY's retatrutide pipeline. | Cautionary setup signal. If the market sold NVO on a beat, LLY faces a similar risk of a "sell the news" reaction unless the Q2 print is a clear, wide beat with guidance raised again. The bar for a positive stock reaction may be higher than the consensus numbers suggest. |
Source: Novo Nordisk Q2 2026 Financial Report (6-K, August 4, 2026); NVO Press Release — "Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook" (August 4, 2026); News Digest (August 4, 2026).
Read-Through Type: Longer-term competitive pipeline risk (maritime not yet approved; no near-term revenue impact on LLY)
Theme | AMGN Commentary (Q2 2026 Earnings Call — August 4, 2026) | LLY Read-Through |
Maritime (Monthly GLP-1) Program | Maritime is "fundamentally different from other GLP-1 therapies" — designed for monthly dosing with potential for "as few as 4 or 6 doses per year." Nine ongoing Phase 3 studies across obesity and related diseases. 2026 described as "a year of very disciplined data generation." Trial enrollment is "strong." | Longer-term competitive risk, not a Q2 2026 factor. Maritime is still in Phase 3 with no approval timeline disclosed. The monthly dosing differentiation is a genuine threat to LLY's weekly injectable franchise if efficacy data are strong, but this is a 2028+ competitive dynamic. |
Switching Study from Weekly GLP-1s | AMGN is running a dedicated Phase 3 study evaluating "switching from weekly GLP-1 therapies to maritime" with the goal of enabling patients to move to "as few as 4 or 6 doses per year." This directly targets patients currently on LLY's Mounjaro/Zepbound. | Strategically notable but not a near-term threat. The switching study is a direct competitive signal, but results are likely 2027+ and approval/launch would be 2028+. LLY's response is its own long-acting program (purpose-built monthly formulations in development). |
Manufacturing Investment | AMGN expects CapEx of ~$2.6B in 2026, "reflecting significant investment in our business to scale manufacturing capacity for volume growth, including for maritime launch." R&D to grow high single digits YoY, including nine Phase 3 maritime trials. | Neutral for LLY Q2. AMGN's manufacturing investment signals confidence in maritime's commercial potential but does not affect LLY's near-term results. Confirms the obesity market is large enough to support multiple well-capitalized competitors. |
Broader Cardiometabolic Strategy | AMGN developing maritime for "diabetes and for heart failure and for ASCVD" — not just weight loss. Mirrors LLY's own multi-indication strategy for tirzepatide and retatrutide. | Confirms the cardiometabolic market is evolving toward multi-indication platforms. LLY's head start with approved indications (T2D, obesity, sleep apnea, HFpEF) and retatrutide's NDA filing in H2 2026 gives it a meaningful lead. |
Source: Amgen Q2 2026 Earnings Call Transcript (August 4, 2026); AMGN Q2 2026 Earnings Release (8-K, August 4, 2026). AMGN reported Q2 EPS of $6.29 vs. $5.62 consensus and sales of $10.05B vs. $9.43B consensus — a strong beat that raised full-year guidance to $22.30–$23.50 EPS.
Read-Through Type: Longer-term competitive pipeline risk (VK2735 not yet approved; oral Phase 3 initiating Q4 2026)
Theme | VKTX Commentary (Q2 2026 Earnings Call — July 29, 2026) | LLY Read-Through |
VK2735 Injectable (VANQUISH Phase 3) | VANQUISH-1 (obesity) and VANQUISH-2 (obesity + T2D) are fully enrolled and on track. Primary endpoint: % change in body weight from baseline after 78 weeks. VK2735 is a dual GLP-1/GIP receptor agonist — same mechanism as tirzepatide. | Longer-term competitive risk. VANQUISH data expected in 2027; if positive, VK2735 injectable would compete directly with Zepbound. However, LLY's manufacturing scale, brand recognition, and multi-indication label give it a durable competitive moat. |
VK2735 Oral Phase 3 (Q4 2026 Initiation) | Viking expects to initiate oral VK2735 Phase 3 in Q4 2026, positioning it as "the first oral formulation of a dual GLP-1/GIP agonist to reach the market." Two studies mirroring VANQUISH; 75% smaller enrollment than injectable Phase 3. | Strategically important but not a near-term LLY threat. Foundayo (orforglipron) is already approved and on market as an oral GLP-1. VK2735 oral would be a dual agonist oral, potentially more efficacious than Foundayo, but approval is likely 2028+. LLY's own oral dual agonist pipeline (LY3493269) is in development. |
Maintenance Dosing Study (Results Expected Q3 2026) | Viking's range-finding maintenance dosing study (weekly, monthly, every-other-week regimens) is "nearing completion" with results expected "later this quarter" (Q3 2026). Results could inform VANQUISH extension studies (late 2026/early 2027). CEO noted retaining "75–80% of weight loss" in maintenance is the key efficacy benchmark. | Neutral for LLY Q2. Maintenance data will be a competitive data point but does not affect LLY's near-term results. LLY's own SURMOUNT-MAINTAIN data for tirzepatide already established the maintenance benchmark. |
VK3019 (Dual Amylin/Calcitonin Agonist) Phase 1 | Phase 1 single ascending dose trial initiated in Q2 2026. Preclinical data showed "impressive effects on body weight" — up to 8% weight reduction in lean rats after single dose. Combination with VK2735 could yield "40–50% improvement in efficacy" and "industry-leading efficacy." Combination clinic entry "next year at the earliest." | Longer-term pipeline watch. A VK2735 + VK3019 combination could be a future competitor to LLY's eloralintide + tirzepatide combination program. However, this is a 2028+ dynamic at the earliest. LLY's eloralintide Phase 2b combination data with tirzepatide expected H2 2026. |
Source: Viking Therapeutics Q2 2026 Earnings Call Transcript (July 29, 2026); VKTX Q2 2026 Earnings Release (July 29, 2026). VKTX reported Q2 net loss of $128.1M ($1.10/share) vs. $65.6M in Q2 2025; R&D expense of $115.8M reflecting accelerating Phase 3 investment. Cash of $502M provides runway into 2028.
Read-Through Type: Direct near-term market read-through (oral GLP-1 competitive dynamics relevant to Foundayo launch)
Theme | NVO Commentary / Market Data (June–July 2026) | LLY Read-Through |
Medicare Patient Preference for Oral GLP-1s | NVO reported (June 24, 2026) that Medicare patients prefer GLP-1 pills over injectables by a 2:1 margin, citing easier integration with existing medication routines. NVO's U.S. chief pushed for broader insurance coverage of weight-loss drugs (June 25, 2026). | Positive for Foundayo. The 2:1 oral preference among Medicare patients directly supports LLY's Foundayo launch thesis — the Medicare Bridge program (launched July 1) could disproportionately benefit Foundayo given patient preference for oral formulations. This is a Q3 2026 tailwind rather than a Q2 driver. |
Oral GLP-1 Pill Competition (Novo vs. Lilly) | NVO and LLY are "competing to win the GLP-1 pill market as they prepare for Medicare coverage" (June 8, 2026). NVO's Wegovy pill reached 5M+ prescriptions since U.S. launch (January 2026 debut). NVO's oral semaglutide has food/water restrictions; Foundayo does not. | Competitive but manageable. NVO's 5M+ prescription head start for oral semaglutide is a real competitive advantage, but Foundayo's no food/water restriction differentiator and superior efficacy vs. oral semaglutide (ACHIEVE-3) give LLY a credible value proposition. The oral market is expanding rapidly, supporting both players. |
GLP-1 Employer Coverage Concerns | Breakthrough GLP-1 weight loss pills "may be a bad thing for employer insurance coverage" as companies may not foot the bill despite rising consumer demand (June 26, 2026). Employer cost concerns are a structural headwind for the category. | Modest negative. LLY's Lilly Employer Connect platform (launched with 15+ independent program administrators) is a direct response to this concern. However, employer coverage friction could slow Foundayo's commercial ramp in H2 2026 if employers are slow to adopt. |
Source: Public news sources (June 8, 24, 25, 26, 2026); NVO Q2 2026 Earnings Release (August 4, 2026).
Peer | Source Date | Read-Through Type | Net Signal for LLY Q2 | Key Takeaway |
NVO (Q2 2026 Results) | August 4, 2026 | Direct / Near-Term | Positive (volume) | GLP-1 volume beat confirms category demand; guidance raise supports LLY's own guidance range; stock reaction risk if LLY prints in-line |
AMGN (Q2 2026 Call) | August 4, 2026 | Competitive Pipeline / Long-Term | Neutral (2028+ risk) | Maritime monthly dosing is a genuine long-term threat; switching study targets LLY patients; no near-term Q2 impact |
VKTX (Q2 2026 Call) | July 29, 2026 | Competitive Pipeline / Long-Term | Neutral (2028+ risk) | Oral dual agonist Phase 3 initiating Q4 2026; maintenance data Q3 2026; no near-term Q2 impact on LLY |
NVO (Oral GLP-1 Market Data) | June 2026 | Direct / Near-Term (Foundayo) | Positive (oral preference) | 2:1 Medicare patient preference for oral GLP-1s supports Foundayo launch thesis; employer coverage friction is a modest headwind |
Disclosures: This document is prepared for informational purposes only. All consensus estimates sourced from Visible Alpha. All insider transaction data sourced from SEC Form 4 filings. Peer commentary sourced from publicly available earnings transcripts, press releases, and news sources as cited. Prepared August 4, 2026.